That’s what an evaluation from PwC finds, no less than with respect to inventory market returns.
Our PwC equal-weight index of fifty pharma firms analyzes the sector’s complete shareholder returns efficiency relative to the S&P 500 Equal Weighted Index. From 2018 via November 2024, the PwC pharma index returned 7.6% to shareholders, in contrast with greater than 15% for the S&P 500. During the last 12 months, this dynamic grew to become much more pronounced with the PwC pharma index returning 13.9% in comparison with 28.7% for the S&P via November 2024.
Unsurprisingly, worth development is very concentrated in only a few firms:
…since 2018, an more and more restricted set of firms have influenced optimistic returns within the prescribed drugs sector. Inside the S&P 500, the so-called “Magnificent 7” accounted for 40% of the rise in worth since 2018. Within the pharma {industry}, this dynamic is much more stark with simply two [leading GLP-1 manufacturers]…accounting for practically 60% of the rise in worth development among the many 50 pharma firms analyzed by PwC.
With the appearance of the IRA and growing stress on value negotiation in lots of international locations, will buyers proceed to fund life science innovators? Let me know your ideas.
